Results 181 to 190 of about 18,552 (255)

Clinical Functional Assignment of TPMT and NUDT15 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1427-1437, November 2026.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) TPMT/NUDT15 Pharmacogene Curation Expert Panel (PCEP) conducted a comprehensive review of clinical, laboratory, and computational evidence to determine the clinical function assignments for TPMT and NUDT15 star alleles.
Bailey M. Tibben   +10 more
wiley   +1 more source

Chloroplast Genome Characterization and Phylogenetic Implications of Reyesia and Salpiglossis (Salpiglossideae, Solanaceae)

open access: yesEcology and Evolution, Volume 16, Issue 11, November 2026.
We generated and compared the complete chloroplast genomes of Reyesia chilensis and Salpiglossis sinuata, two representative species of the tribe Salpiglossideae (subfamily Cestroideae) within Solanaceae. Comparative plastome analyses revealed highly conserved genome organization, codon usage, and repeat composition, while phylogenetic analyses ...
Jie Huang   +3 more
wiley   +1 more source

MONDE·T: A database and interactive webserver for non‐standard amino acids and peptide components in the PDB

open access: yesProtein Science, Volume 35, Issue 11, November 2026.
Abstract Non‐standard amino acids (ncAAs) together with synthetic additions (like caps and linkers) are of wide interest for protein design and pharmaceutical optimization, as they can improve physicochemical properties and possibly reshape protein structure. Their inclusion in experimental structures has not been explored systematically.
Alex Waldherr   +2 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy